Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo
Нема приказа
Аутори
Aranđelović, SandraBjelogrlić, Snežana K.
Malesevic, N. N.
Tešić, Živoslav Lj.
Radulović, Siniša
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Purpose: To investigate the antitumor activity of two newly synthesized ruthenium(III) [Ru(III)] compounds carrying bidentate ligands: (acac)-acetylacetonate, [Ru(acac)(3)], and (tfac)-trifluoroacetylacetonate [Ru(tfac)(3)]. Materials and methods: The activity of ruthenium(III) analogues was evaluated on HeLa, B16, and Femx cell lines for cytotoxicity in vitro using MTT assay, and inhibition on tumor invading ability in vitro using cell migration and invasion assays, whereas inhibition of tumor growth in vivo was estimated on advanced B16 murine melanoma model. Both compounds were also investigated in combinations with cisplatin, oxaliplatin, or poly ADP-ribose polymerase-1 (PARP-1) inhibitor, in order to determine the pattern of mutual interactions. Results: Applied as single drugs, Ru(tfac)(3) showed high cytotoxic activity against HeLa and Femx cell lines, while Ru(acac)(3) did not reach the IC(50) on any of the cell lines tested. In combinations, Ru(acac)(3) with cisplalin gained s...ynergistic interaction, antagonistic with oxaliplatin, and of different kind with (PARP-1) inhibitor in concentration-and cell line-dependent manner. Ru(acac)(3) exhibited inhibition of HeLa cell migration and gelatinolytic activity of MMP-2 and MMP-9. Ru(tfac)(3) complexes didnot induce significant reduction of melanoma growth in vivo, whereas Ru(acac)(3) did, but the latter failed to contribute in lifespan improvement. Conclusion: The investigated ruthenium complexes showed different levels of antitumor activity in vitro and in vivo, implicating on different mechanisms of their action as well as diverse perspectives in cancer treatment.
Кључне речи:
antitumor activity in vivo/in vitro / MMP / ruthenium(III)-beta-diketonatoИзвор:
Journal of BUON / Journal of the Balkan Oncology, 2009, 14, 2, 271-279Издавач:
- Zerbinis Medical Publ, Athens
Колекције
Институција/група
Hemijski fakultet / Faculty of ChemistryTY - JOUR AU - Aranđelović, Sandra AU - Bjelogrlić, Snežana K. AU - Malesevic, N. N. AU - Tešić, Živoslav Lj. AU - Radulović, Siniša PY - 2009 UR - https://cherry.chem.bg.ac.rs/handle/123456789/994 AB - Purpose: To investigate the antitumor activity of two newly synthesized ruthenium(III) [Ru(III)] compounds carrying bidentate ligands: (acac)-acetylacetonate, [Ru(acac)(3)], and (tfac)-trifluoroacetylacetonate [Ru(tfac)(3)]. Materials and methods: The activity of ruthenium(III) analogues was evaluated on HeLa, B16, and Femx cell lines for cytotoxicity in vitro using MTT assay, and inhibition on tumor invading ability in vitro using cell migration and invasion assays, whereas inhibition of tumor growth in vivo was estimated on advanced B16 murine melanoma model. Both compounds were also investigated in combinations with cisplatin, oxaliplatin, or poly ADP-ribose polymerase-1 (PARP-1) inhibitor, in order to determine the pattern of mutual interactions. Results: Applied as single drugs, Ru(tfac)(3) showed high cytotoxic activity against HeLa and Femx cell lines, while Ru(acac)(3) did not reach the IC(50) on any of the cell lines tested. In combinations, Ru(acac)(3) with cisplalin gained synergistic interaction, antagonistic with oxaliplatin, and of different kind with (PARP-1) inhibitor in concentration-and cell line-dependent manner. Ru(acac)(3) exhibited inhibition of HeLa cell migration and gelatinolytic activity of MMP-2 and MMP-9. Ru(tfac)(3) complexes didnot induce significant reduction of melanoma growth in vivo, whereas Ru(acac)(3) did, but the latter failed to contribute in lifespan improvement. Conclusion: The investigated ruthenium complexes showed different levels of antitumor activity in vitro and in vivo, implicating on different mechanisms of their action as well as diverse perspectives in cancer treatment. PB - Zerbinis Medical Publ, Athens T2 - Journal of BUON / Journal of the Balkan Oncology T1 - Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo VL - 14 IS - 2 SP - 271 EP - 279 UR - https://hdl.handle.net/21.15107/rcub_cherry_994 ER -
@article{ author = "Aranđelović, Sandra and Bjelogrlić, Snežana K. and Malesevic, N. N. and Tešić, Živoslav Lj. and Radulović, Siniša", year = "2009", abstract = "Purpose: To investigate the antitumor activity of two newly synthesized ruthenium(III) [Ru(III)] compounds carrying bidentate ligands: (acac)-acetylacetonate, [Ru(acac)(3)], and (tfac)-trifluoroacetylacetonate [Ru(tfac)(3)]. Materials and methods: The activity of ruthenium(III) analogues was evaluated on HeLa, B16, and Femx cell lines for cytotoxicity in vitro using MTT assay, and inhibition on tumor invading ability in vitro using cell migration and invasion assays, whereas inhibition of tumor growth in vivo was estimated on advanced B16 murine melanoma model. Both compounds were also investigated in combinations with cisplatin, oxaliplatin, or poly ADP-ribose polymerase-1 (PARP-1) inhibitor, in order to determine the pattern of mutual interactions. Results: Applied as single drugs, Ru(tfac)(3) showed high cytotoxic activity against HeLa and Femx cell lines, while Ru(acac)(3) did not reach the IC(50) on any of the cell lines tested. In combinations, Ru(acac)(3) with cisplalin gained synergistic interaction, antagonistic with oxaliplatin, and of different kind with (PARP-1) inhibitor in concentration-and cell line-dependent manner. Ru(acac)(3) exhibited inhibition of HeLa cell migration and gelatinolytic activity of MMP-2 and MMP-9. Ru(tfac)(3) complexes didnot induce significant reduction of melanoma growth in vivo, whereas Ru(acac)(3) did, but the latter failed to contribute in lifespan improvement. Conclusion: The investigated ruthenium complexes showed different levels of antitumor activity in vitro and in vivo, implicating on different mechanisms of their action as well as diverse perspectives in cancer treatment.", publisher = "Zerbinis Medical Publ, Athens", journal = "Journal of BUON / Journal of the Balkan Oncology", title = "Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo", volume = "14", number = "2", pages = "271-279", url = "https://hdl.handle.net/21.15107/rcub_cherry_994" }
Aranđelović, S., Bjelogrlić, S. K., Malesevic, N. N., Tešić, Ž. Lj.,& Radulović, S.. (2009). Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo. in Journal of BUON / Journal of the Balkan Oncology Zerbinis Medical Publ, Athens., 14(2), 271-279. https://hdl.handle.net/21.15107/rcub_cherry_994
Aranđelović S, Bjelogrlić SK, Malesevic NN, Tešić ŽL, Radulović S. Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo. in Journal of BUON / Journal of the Balkan Oncology. 2009;14(2):271-279. https://hdl.handle.net/21.15107/rcub_cherry_994 .
Aranđelović, Sandra, Bjelogrlić, Snežana K., Malesevic, N. N., Tešić, Živoslav Lj., Radulović, Siniša, "Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo" in Journal of BUON / Journal of the Balkan Oncology, 14, no. 2 (2009):271-279, https://hdl.handle.net/21.15107/rcub_cherry_994 .